⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MGTX News
MeiraGTx Holdings plc Ordinary Shares
Form 8-K
sec.gov
MGTX
MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia
globenewswire.com
MGTX
MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026
globenewswire.com
MGTX
Form 8-K
sec.gov
MGTX
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results
globenewswire.com
MGTX
LLY
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
globenewswire.com
SUPN
MGTX
JNJ
ARWR
ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy
prnewswire.com
MGTX
Marengo to Present Initial Results from Invikafusp Alfa and TRODELVY® Combination Study, STARt-002, at the 2025 San Antonio Breast Cancer Symposium
prnewswire.com
GILD
MGTX
Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference
prnewswire.com
MGTX
MeiraGTx Reports Third Quarter 2025 Financial and Operational Results
globenewswire.com
MGTX